ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Patient-Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organoids as next-generation models for investigating intracranial tumours.Molecular brain · 2026Review
- A Patient-Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Adamantinomatous craniopharyngioma (ACP), a benign yet clinically challenging neoplasm situated in sellar-suprasellar region, frequently causes hypothalamic dysfunction. Despite the identification of molecular alterations in ACP, the absence of robust research models has impeded the advancement of targeted therapies. Herein, the development of a large-scale ACP biobank comprising 54 patient-derived organoids (PDOs) is presented, achieves with a notable 90% success rate. Comprehensive characterization using hematoxylin and eosin (H&E) staining, immunofluorescence staining, and whole-exome sequencing (WES) demonstrates that PDOs faithfully recapitulate key histoarchitectural features, molecular marker expression profiles, and somatic mutational landscapes of corresponding parental tumors. Drug sensitivity screening reveals diverse responses of PDOs to the drugs tested, with Ceritinib exhibiting potent and consistent anti-tumor activity across seventeen PDOs evaluated. Further mechanistic investigations utilizing RNA transcriptomic sequencing have elucidated that Ceritinib inhibits PDO growth by downregulating the IGF-1R/PI3K/AKT/GSK-3β/β-catenin signaling axis. Additionally, a retrospective analysis of two Ceritinib-treated clinical cases reveals tumor growth with treatment before any possible therapeutic effects are observed, highlighting the need for caution and careful monitoring in treating ACP patients. Collectively, these findings demonstrate that ACP PDOs effectively preserve the biological characteristics of original tumors, thereby providing a valuable platform for developing precision therapies for ACP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.